- | Celularity
Clinical Potential of onCARlytics Under Exploration in Solid Tumors
“We believe the synergy between Celularity’s placental-derived cells and our OnCARlytic platform has the potential to shift the cellular medicine paradigm,” Leslie Chong, managing director and chief executive officer of Imugene, stated in a press release.
- | Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals – New Positive Patient-Level Data In AATD Liver Disease
Dr. Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study of ARO-AAT, an RNA therapeutic being co-developed by the company and Takeda, in patients with liver disease caused by alpha-1 antitrypsin deficiency (AATD). He also talks about the company’s RNAi platform.
- | BeyondSpring Pharmaceuticals
Shares of BeyondSpring skyrocket on new, positive cancer drug trial results
On Wednesday, BeyondSpring, a small New York biotech with an offbeat approach to immunotherapy, announced its lead drug significantly extended non-small cell lung cancer patients’ lives in a large trial. Although the company did not release the exact survival data, it said that nearly twice as many patients were alive after two years on the drug arm than on the standard-of-care arm.
- | Leyden Labs
Intranasal Prophylactics For Flu & Coronavirus With Leyden Labs’ Koenraad Wiedhaup
As Leyden Labs Founder & CEO Koenraad Wiedhaup puts it, we breathe in galaxies of viruses on a daily basis. As those viruses multiply and mutate, our approach to mitigating their risks is largely reactive.
- | TFF Pharmaceuticals
Austin company works to launch COVID-19 antibody treatment in new inhaler form
Dale Christensen, with Austin-based drug developer TFF Pharmaceuticals, says they’ve got an easy solution to getting a monoclonal antibody treatment straight to your doorstep — rather than being hooked up to a machine and IV.
- | Cidara Therapeutics
Emerging Drug-Resistant Fungi Threat Offset by Cidara’s Phase III Antifungal Therapy
The cure for this new threat may rest with Cidara Therapeutics’ new antifungal drug, rezafungin. It currently is completing two Phase III trials. One treats candidemia and invasive candidiasis. On the other, rezafungin is used as a prophylactic for the prevention of fungal infections in a high-risk hematology setting. It shows efficacy against Candida spp., Aspergillus spp., Pneumocystis spp. and dermatophytes, can be administered safely at high doses, and it can clear the body of infection quickly.
- | Renovacor
Physics To Genetics: New Treatments For Hereditary Heart Disease
“Renovacor is in a similar situation to the one MyoKardia was in five years ago,” says Dr. Semigran. “We have knowledge of the mechanism of action of dilated cardiomyopathy, where there’s an inadequate amount of a required protein for the heart muscle to function correctly. And fortunately, I think the field of selective gene therapy for the heart has evolved to the point that we’ve got a pretty good chance of targeting the underlying abnormality of the segment of the cardiomyopathy population with a BAG3-associated condition.”
- | Scynexis
Can Ibrexafungerp Treat Candida Auris?
The therapy was developed by Jersey City, New Jersey-based biotechnology company, Scynexis. The company has also been studying ibrexafungerp in its CARES study in hospitalized patients with C. auris.
